111 related articles for article (PubMed ID: 11880179)
1. Down-regulation of von Hippel-Lindau protein in N-nitroso compound-induced rat non-clear cell renal tumors.
Shiao YH; Ramakrishna G; Anderson LM; Perantoni AO; Rice JM; Diwan BA
Cancer Lett; 2002 May; 179(1):33-8. PubMed ID: 11880179
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the VHL gene from potassium bromate-induced rat clear cell renal tumors.
Shiao YH; Kamata SI; Li LM; Hooth MJ; DeAngelo AB; Anderson LM; Wolf DC
Cancer Lett; 2002 Dec; 187(1-2):207-14. PubMed ID: 12359370
[TBL] [Abstract][Full Text] [Related]
3. von Hippel-Lindau gene mutations in N-nitrosodimethylamine-induced rat renal epithelial tumors.
Shiao YH; Rice JM; Anderson LM; Diwan BA; Hard GC
J Natl Cancer Inst; 1998 Nov; 90(22):1720-3. PubMed ID: 9827526
[TBL] [Abstract][Full Text] [Related]
4. Polymerase chain reaction-single-strand conformation polymorphism analysis for the VHL gene in chemically induced kidney tumors of rats using intron-derived primers.
Shiao YH; Diwan BA; Perantoni AO; Calvert RJ; Zbar B; Lerman MI; Rice JM
Mol Carcinog; 1997 Aug; 19(4):230-5. PubMed ID: 9290699
[TBL] [Abstract][Full Text] [Related]
5. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
6. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
9. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutation of the tuberous sclerosis (Tsc2) tumor suppressor gene in chemically induced rat renal carcinoma cell.
Urakami S; Tokuzen R; Tsuda H; Igawa M; Hino O
J Urol; 1997 Jul; 158(1):275-8. PubMed ID: 9186374
[TBL] [Abstract][Full Text] [Related]
11. Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.
Zatyka M; Morrissey C; Kuzmin I; Lerman MI; Latif F; Richards FM; Maher ER
J Med Genet; 2002 Jul; 39(7):463-72. PubMed ID: 12114475
[TBL] [Abstract][Full Text] [Related]
12. Should endolymphatic sac tumors be considered part of the von Hippel-Lindau complex? Pathology case report.
Tibbs RE; Bowles AP; Raila FA; Fratkin JD; Hutchins JB
Neurosurgery; 1997 Apr; 40(4):848-55; discussion 855. PubMed ID: 9092862
[TBL] [Abstract][Full Text] [Related]
13. Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus.
Walker C; Ahn YT; Everitt J; Yuan X
Mol Carcinog; 1996 Feb; 15(2):154-61. PubMed ID: 8599582
[TBL] [Abstract][Full Text] [Related]
14. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas.
Dannenberg H; De Krijger RR; van der Harst E; Abbou M; IJzendoorn Y; Komminoth P; Dinjens WN
Int J Cancer; 2003 Jun; 105(2):190-5. PubMed ID: 12673678
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of renal carcinoma: the nutri-genetic approach].
Junien C; Dupret JM; Gallou C; Longuemaux S; Richard S; Saquet C; Krishnamoorty R; Delomenie C; Droz D; Bouvier R; Chauveau D; Joly D; Grunfeld JP; Chretien Y; Mejean A; Beroud C
J Soc Biol; 2000; 194(1):29-38. PubMed ID: 11107547
[TBL] [Abstract][Full Text] [Related]
16. VHL and kidney cancer.
Ohh M; Kaelin WG
Methods Mol Biol; 2003; 222():167-83. PubMed ID: 12710686
[No Abstract] [Full Text] [Related]
17. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
18. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
19. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
20. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
